Study of Tumor Samples From Patients With Lung Cancer
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at tumor samples from patients with lung cancer.
Genetic: gene expression analysis
Genetic: mutation analysis
Genetic: polymerase chain reaction
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
|Official Title:||A Pilot Project to Study the Expression of c-MET and p53 in Resected Lung Adenocarcinoma Specimens|
- Correlation of c-Met expression and stage and overall survival [ Designated as safety issue: No ]
- Correlation of c-Met expression and and biomarkers with survival [ Designated as safety issue: No ]
- Correlation of c-Met expression and circulating c-Met and hepatocyte growth factor [ Designated as safety issue: No ]
- Prognostic implications of circulating markers [ Designated as safety issue: No ]
- Levels of circulating Met and HGF in serum before and after surgery (when available) [ Designated as safety issue: No ]
|Study Start Date:||September 2008|
|Estimated Primary Completion Date:||July 2009 (Final data collection date for primary outcome measure)|
- To determine the correlation between c-Met expression, mutation and amplification, with stage and overall survival in patients with adenocarcinoma (AC) of the lung.
- To determine the correlation with epithelial mesenchymal transition (EMT), EGFR mutations and expression, Kras mutations, p53 mutations, c-CBL protein expression, mutation, loss of heterozygosity (LOH), DUB3 expression & regulation, and ALK translocation, with respect to survival.
- To determine the correlation with circulating c-Met and HGF in AC and evaluate prognostic implications of circulating markers in AC of lung.
- To determine (when available) levels of circulating Met and HGF in serum before and after surgery.
OUTLINE: This is a multicenter study.
Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for mutation analysis of c-Met, EGFR, and K-ras. DNA is examined by PCR, followed by agarose gel electrophoresis; gene amplification of c-Met is examined by real time quantitative PCR; met/HF protein in serum is examined by ELISA; and c-Met, EGFR, p53, c-CBL, DUB3 enzyme, and ALK, and epithelial mesenchymal transition examined by IHC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00900328
|Study Chair:||Ravi Salgia, MD, PhD||University of Chicago|